/Lists

Biotech Late Stage Investors & VC Firms

360 firms in this list, with a median first check of $1M. 82 of them lead rounds. Generated from verified public data and updated continuously.

Sofinnova Ventures
Menlo ParkSeed–Late Stage$100K – $15M
48 people
Foresite Capital
West HollywoodSeed–Late Stage
44 people
Sixth Street
San FranciscoGrowth–Late Stage$50M – $2.5B
78 people
Longitude Capital
Menlo ParkSeries A–Late Stage$10M – $30M
62 people
SK Capital Partners
New YorkGrowth–Late Stage
95 people
Cerity Partners Ventures
New YorkSeed–Late Stage
61 people
Bayern Kapital
LandshutSeed–Late Stage$275K – $55M
46 people
Vivo Capital
Palo AltoSeed–Late Stage$10M – $50M
58 people
TPG
San FranciscoGrowth–Late Stage
70 people
Dementia Discovery Fund
LondonSeed–Late Stage
81 people
Birch Hill Equity Partners Management Inc.
TorontoGrowth–Late Stage$75M – $3B
74 people
Novo Holdings
HellerupSeed–Late Stage$1.1M – $54M
48 people
Kiwoom Investment
SeoulSeed–Late Stage
27 people
Blackstone Life Sciences
New YorkSeries A–Late Stage$20M – $60M
82 people
Obvious Ventures
San FranciscoPre-Seed–Late Stage$250K – $6M
40 people
Versant Ventures
San FranciscoSeed–Late Stage$250K – $5M
55 people
Thompson Street Capital Partners
St. LouisGrowth–Late Stage$50M – $500M
62 people
Altas Partners
TorontoGrowth–Late Stage
84 people
5AM Ventures
San FranciscoSeed–Late Stage$100K – $4M
41 people
Stifel Venture Banking
San FranciscoSeed–Late Stage
75 people
Kreos Capital
LondonSeries A–Late Stage
43 people
EQT Life Sciences
AmsterdamSeed–Late Stage$11M – $66M
59 people
SMBC Venture Capital
TokyoPre-Seed–Late Stage
27 people
Tesi (Finnish Industry Investment Ltd)
HelsinkiSeed–Late Stage$5.4M – $16.2M
24 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.